The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Open accessAbstract
Background: Camrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the safety and efficacy of camrelizumab plus neoadjuvant chemotherapy, using pathologically complete response (pCR) as primary endpoint, in the treatment for locally advanced ESCC. Methods: Patients with locally advanced but resectable thoracic ESCC, staged as T1b-4a, N2-3 (≥3 stations), and M0 or M1 lymph node metastasis (confined to the supraclavicular lymph nodes) were enrolled. Eligible patients received intravenous camrelizumab (200 mg, day 1) plus nab-paclitaxel (100 mg/m 2, day 1, 8, 15) and carboplatin (area under curve of 5 mg/mL/min, day 1) of each 21-days cycle, for two cycles before surgery. The primary endpoint is pCR rate in the per-protocol population. Safety was assessed in the modified intention-to-treat population that was treated with at least one dose of camrelizumab. Results: From November 20, 2019 to December 22, 2020, 60 patients were enrolled. 55 (91.7%) patients completed the full two-cycle treatment successfully. 51 patients underwent surgery and R0 resection was achieved in 50 (98.0%) patients. pCR (ypT0N0) was identified in 20 (39.2%) patients and 5 (9.8%) patients had complete response of the primary tumor but residual disease in lymph nodes alone (ypT0N+). 58 patients (96.7%) had any-grade treatment-related adverse events (TRAEs), with the most common being leukocytopenia (86.7%). 34 patients (56.7%) had adverse events of grade 3 or worse, and one patient (1.7%) occurred a grade 5 adverse event. There was no in-hospital and postoperative 30-day as well as 90-day mortality. Conclusions: The robust antitumor activity of camrelizumab and chemotherapy was confirmed and demonstrated without unexpected safety signals. Our findings established camrelizumab and chemotherapy as a promising neoadjuvant treatment for locally advanced ESCC. Trial registration number: ChiCTR1900026240.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Cooper, J. S., Guo, M. D., Herskovic, A., Macdonald, J. S., Martenson, Jr., Al-Sarraf, M., Byhardt, R., Russell, A. H., Beitler, J. J., Spencer, S., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1623 · Cited by 1,957
A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., & Hennessy, T. P. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350702 · Cited by 1,950
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827
Self-citationSjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., & Gebski, V. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70142-5 · Cited by 1,647
Low, D. E., Alderson, D., Cecconello, I., Chang, A. C., Darling, G. E., D'Journo, X. B., Griffin, S. M., Hölscher, A. H., Hofstetter, W. L., Jobe, B. A., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001098 · Cited by 1,176
Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0033 · Cited by 1,059
Dueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030
Yang, H., Liu, H., Chen, Y., Zhu, C., Fang, W., Yu, Z., Mao, W., Xiang, J., Han, Y., Chen, Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.1483 · Cited by 995
Japanese Classification of Esophageal Cancer, 11th Edition: part I
Japan Esophageal Society (2017) · Esophagus · doi:10.1007/s10388-016-0551-7 · Cited by 929
Luo, H., Lu, J., Bai, Y., Mao, T., Wang, J., Fan, Q., Zhang, Y., Zhao, K., Chen, Z., Gao, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.12836 · Cited by 803
Self-citationHuang, J., Xu, J., Chen, Y., Zhuang, W., Zhang, Y., Chen, Z., Chen, J., Zhang, H., Niu, Z., Fan, Q., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30110-8 · Cited by 591
Self-citationRozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Chirieac, L. R., Swisher, S. G., Ajani, J. A., Komaki, R. R., Correa, A. M., Morris, J. S., Roth, J. A., Rashid, A., Hamilton, S. R., & Wu, T. (2005) · Cancer · doi:10.1002/cncr.20916 · Cited by 495
Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01188-3 · Cited by 436
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Lu, Z., Zou, J., Li, S., Topper, M. J., Tao, Y., Zhang, H., Jiao, X., Xie, W., Kong, X., Vaz, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2054-x · Cited by 330
Self-citationLi, C., Zhao, S., Zheng, Y., Han, Y., Chen, X., Cheng, Z., Wu, Y., Feng, X., Qi, W., Chen, K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.039 · Cited by 324
Self-citationvan den Ende, T., de Clercq, N. C., van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4443 · Cited by 275
Huang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 203
Self-citationBai, X., Hu, J., Betof Warner, A., Quach, H. T., Cann, C. G., Zhang, M. Z., Si, L., Tang, B., Cui, C., Yang, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1283 · Cited by 185
Self-citationLiu, S., Wen, J., Yang, H., Li, Q., Chen, Y., Zhu, C., Fang, W., Yu, Z., Mao, W., Xiang, J., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.002 · Cited by 117
Use of a positional therapy device significantly improves nocturnal gastroesophageal reflux symptoms
Allampati, S., López, R., Thota, P., et al. (2016) · Diseases of the Esophagus · doi:10.1111/dote.12495 · Cited by 89
Blom, R. L. G. M., Sosef, M. N., Nap, M., Lammering, G., van den Berkmortel, F. W. P. J., Hulshof, M. C. C. M., Meijer, S. L., Wilmink, H. W., & Henegouwen, M. I. V. B. (2013) · Diseases of the Esophagus · doi:10.1111/dote.12110 · Cited by 48
Mu, L., Song, Y., Zhao, K., Liu, Y., Fan, Q., Wang, X., Li, Q., Wang, X., & Huang, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13913 · Cited by 28
Cited by
Qin, J., Xue, L., Hao, A., Guo, X., Jiang, T., Ni, Y., Liu, S., Chen, Y., Jiang, H., Zhang, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03064-w · Cited by 254
Self-citationLiu, L., Liang, L., Luo, Y., Han, J., Lu, D., Cai, R., Sethi, G., & Mai, S. (2024) · Research · doi:10.34133/research.0529 · Cited by 22
Metadata
- Authors
- Liu, J., Yang, Y., Liu, Z., Fu, X., Cai, X., Li, H., Zhu, L., Shen, Y., Zhang, H., Sun, Y., Chen, H., Yu, B., Zhang, R., Shao, J., Zhang, M., & Li, Z.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2022-03
- Volume
- 10
- Issue
- 3
- Pages
- e004291
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W4220823757
- Cited by
- 282
- References
- 29
- FWCI
- 48.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.